Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report) insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the completion of the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Kura Oncology Price Performance
Shares of NASDAQ KURA opened at $8.03 on Friday. Kura Oncology, Inc. has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The stock has a market cap of $624.41 million, a price-to-earnings ratio of -3.40 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm’s 50-day simple moving average is $9.02 and its 200 day simple moving average is $15.58.
Kura Oncology (NASDAQ:KURA – Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.64) by $0.01. During the same quarter in the previous year, the business posted ($0.50) earnings per share. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Kura Oncology
Wall Street Analysts Forecast Growth
Several analysts have issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research report on Monday, November 4th. HC Wainwright boosted their price target on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, November 21st. UBS Group started coverage on Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective for the company. Finally, Scotiabank cut their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $27.38.
Check Out Our Latest Analysis on Kura Oncology
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.
Read More
- Five stocks we like better than Kura Oncology
- 3 Stocks to Consider Buying in October
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Growth Stocks: What They Are, Examples and How to Invest
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- What Makes a Stock a Good Dividend Stock?
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.